Transdermal drug delivery system and preparation method and application thereof

A transdermal drug delivery system and manganese dioxide technology, applied in the field of medicine, can solve problems such as large side effects and poor effects, and achieve the effects of reducing side effects, improving therapeutic effects, and realizing imaging diagnosis.

Pending Publication Date: 2022-01-04
SHENZHEN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of the above deficiencies in the prior art, the object of the present invention is to provide a transdermal drug delivery system and its preparation method and application, aiming to solve the problem that the existing methotrexate is used for the treatment of rheumatoid arthritis, which is poor in effect and Problems with large side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal drug delivery system and preparation method and application thereof
  • Transdermal drug delivery system and preparation method and application thereof
  • Transdermal drug delivery system and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] A kind of preparation method of transdermal drug delivery system

[0054] 1. PDA@MnO 2 Preparation of nanoparticles:

[0055] Stir 2mL of ammonia water, 40mL of ethanol, and 90mL of deionized water at room temperature for 0.5h, then add 0.5g of dopamine hydrochloride (DA) and 10mL of deionized water, stir for 24 hours, wash with deionized water three times after centrifugation, 70 Drying at ℃ for 24 hours to prepare polydopamine (PDA) nanospheres;

[0056] Disperse 50mg of PDA in deionized water, add 0.5g of potassium permanganate and 50mL of concentrated sulfuric acid and stir for 30min, then transfer to a flask and continue to stir at 90°C for 1h, wash with deionized water three times, and dry at 70°C for 24 hours. Preparation of PDA@MnO 2 nanoparticles.

[0057] 2. Preparation of PDMS female mold:

[0058] According to the shape, quantity, and size of the microneedles, the male mold of the microneedle patch is prepared by 3D printing technology; the polydimethyl...

Embodiment 2

[0063] A kind of preparation method of transdermal drug delivery system

[0064] 1. PDA@MnO 2 Preparation of nanoparticles:

[0065] Stir 2mL of ammonia water, 40mL of ethanol, and 90mL of deionized water at room temperature for 0.5h, then add 0.5g of dopamine hydrochloride (DA) and 10mL of deionized water, stir for 24 hours, wash with deionized water three times after centrifugation, 70 Drying at ℃ for 24 hours to prepare polydopamine (PDA) nanospheres;

[0066] Disperse 50mg of PDA in deionized water, add 0.5g of potassium permanganate and 50mL of concentrated sulfuric acid and stir for 30min, then transfer to a flask and continue to stir at 90°C for 1h, wash with deionized water three times, and dry at 70°C for 24 hours. Preparation of PDA@MnO 2 nanoparticles.

[0067] 2. Preparation of PDMS female mold:

[0068] According to the shape, quantity, and size of the microneedles, the male mold of the microneedle patch is prepared by 3D printing technology; the polydimethyl...

Embodiment 3

[0073] A kind of preparation method of transdermal drug delivery system

[0074] 1. PDA@MnO 2 Preparation of nanoparticles:

[0075] Stir 2mL of ammonia water, 40mL of ethanol, and 90mL of deionized water at room temperature for 0.5h, then add 0.5g of dopamine hydrochloride (DA) and 10mL of deionized water, stir for 24 hours, wash with deionized water three times after centrifugation, 70 Drying at ℃ for 24 hours to prepare polydopamine (PDA) nanospheres;

[0076] Disperse 50mg of PDA in deionized water, add 0.5g of potassium permanganate and 50mL of concentrated sulfuric acid and stir for 30min, then transfer to a flask and continue to stir at 90°C for 1h, wash with deionized water three times, and dry at 70°C for 24 hours. Preparation of PDA@MnO 2 nanoparticles.

[0077] 2. Preparation of PDMS female mold:

[0078] According to the shape, quantity, and size of the microneedles, the male mold of the microneedle patch is prepared by 3D printing technology; the polydimethyl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a transdermal drug delivery system and a preparation method and application thereof. The preparation method comprises the following steps that polydopamine composite manganese dioxide nanoparticles are provided; a PDMS female mold is prepared; and methotrexate, a high polymer material and the polydopamine composite manganese dioxide nanoparticles are mixed, a mixture is added into the PDMS female mold, drying treatment is carried out, demolding is carried out to form a microneedle patch containing methotrexate and the polydopamine composite manganese dioxide nanoparticles, and the transdermal drug delivery system is obtained. According to the transdermal drug delivery system, methotrexate and the PDA@MnO2 nanoparticles can be effectively delivered into the skin, the side effect of methotrexate can be reduced, the treatment effect of rheumatoid arthritis can further be improved by removing active oxygen through the PDA@MnO2 nanoparticles, and MRI imaging enhancement is realized through manganese ions, so that the imaging diagnosis of the rheumatoid arthritis is realized.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a transdermal drug delivery system and its preparation method and application. Background technique [0002] Rheumatoid arthritis (RA) is an inflammatory autoimmune disease with complex etiology. During the pathogenesis of RA, inflammatory cytokines, inflammatory cells, and fibroblast synoviocytes (FLSs) interact to cause pannus formation and synovial hyperplasia. In addition, oxidative stress also plays an important role in its pathology, eventually leading to Destruction of subchondral bone and cartilage. [0003] Methotrexate is an inhibitor of dihydrofolate reductase, which can inhibit the metabolism of purine and pyrimidine, reduce the proliferation of antigen-dependent T lymphocytes, increase the release of extracellular adenosine, and promote the inhibition of inflammatory reactions mediated by adenosine. It is convenient to take and low in price. It is the first-line d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/519A61K33/32A61K47/32A61K47/36A61K47/34A61P19/02A61P29/00A61K49/12A61K49/18
CPCA61K9/7023A61K9/0014A61K31/519A61K33/32A61K47/32A61K47/36A61K47/34A61P19/02A61P29/00A61K49/12A61K49/1857A61K2300/00
Inventor 董海峰武超雄
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap